For instance, ICB, such as anti-PD-1, anti-PD-L1, and anti-CTLA-4, has been shown to induce remarkable responses in approximately 15% of CRC patients with microsatellite instability-high (MSI-H) and/or deficient mismatch repair (dMMR). Here, CTLA4 is linked to colorectal carcinoma.